Novo Nordisk Raises Full-Year Outlook: How the Wegovy Pill Is Driving the Recovery

The Danish pharmaceutical company Novo Nordisk sent an important signal of operational stabilization with its third-quarter 2026 results. After a period marked by production bottlenecks and intense competition in obesity drugs, management raised its full-year guidance for 2026. The main driver of this development is the successful market launch of the Wegovy pill, which significantly exceeded market expectations in the third quarter.

Strong operating quarter thanks to oral Wegovy version

In the third quarter of 2026, Novo Nordisk reported adjusted group revenue of DKK 79.2 billion, which corresponds to an increase of 6 percent in kroner terms and 4 percent at constant exchange rates. Adjusted operating profit (EBIT) rose by 27 percent at constant exchange rates to DKK 31.72 billion. The obesity division was the key growth driver, with total revenue increasing by 22 percent at constant exchange rates to DKK 26.15 billion. The Wegovy pill (oral semaglutide), launched in January 2026, contributed DKK 5.394 billion in the third quarter alone, thereby beating consensus estimates. In the important U.S. market, the oral version captured around 80 percent of all new prescriptions in the segment for oral fat-loss drugs, according to the company.

Full-year guidance raised and special items

Due to the dynamic sell-through of the Wegovy pill, management adjusted its expectations for full-year 2026. For both adjusted revenue and adjusted operating profit, Novo Nordisk now expects development of -2 percent to +2 percent at constant exchange rates (previously: -6 percent to 0 percent). Free cash flow for full-year 2026 is estimated at DKK 60 billion to DKK 70 billion. On the downside, balance-sheet special write-downs totaling DKK 8.7 billion — including on pipeline candidate Ziltivekimab as well as adjustments in the manufacturing network — weighed on reported unadjusted operating profit.

Significance for investors and strategic direction

The success of the Wegovy pill not only relieves capacity pressure for injectable products, but also strengthens Novo Nordisk (ISIN DK0062498333 for the B share; ISIN US6701002056 for the U.S. ADRs) in the tough competition with U.S. rival Eli Lilly. Although the U.S. listings rose by a little over 5 to 7 percent on the day of publication, the share price in 2026 still remains noticeably below its January 2026 high. For investors, alongside the expansion of the Wegovy pill to more than 20 markets by mid-2027, the phase planning for the follow-up combination drug CagriSema is moving into focus.

The third-quarter figures show that Novo Nordisk has found an effective lever with the oral semaglutide dosage form to secure market share and reactivate growth. For private investors, the raised guidance provides a solid basis for an operational recovery, although the one-off effects in reported profit and the high level of competitive intensity should be monitored.